Aggressive treatment of metastasis to the parotid. by Raut, V. et al.
The Ulster Medical Journal, Volume 73, No. 2, pp. 85-88, November 2004.
Aggressive treatment ofmetastasis to the parotid
V Raut, AR Sinnathuray, WJ Primrose
Accepted 20 October 2004
SUMMARY
Objectives: Assess the value ofaggressively treating metastatic lesions in the parotid, taking into
account the histology of the disease.
Study Design: Retrospective analysis of 13 patients diagnosed with metastasis to the parotid
treated by one surgeon in a tertiary referral head and neck unit in the United Kingdom.
Methods: The following variables were reviewed and tabulated: age, sex, histology, latent period
to secondary tumour, treatment instituted, postoperative facial nerve outcome, follow-up and
survival.
Results: Twelvepatientsweretreatedaggressivelywithatleasttotalparotidectomyandadjunctive
therapy,whilstonepatientrequiredonlyasuperficialparotidectomy. Tenpatientshadmetastatic
cutaneoustumours,andthreehadmetastaticadenocarcinoma. Sevenofthese 13patients (53.8%)
are alive and well (six had metastatic cutaneous tumours, one had metastatic adenocarcinoma).
Four patients succumbed to tumour (two had metastatic cutaneous tumours and two had
metastatic adenocarcinoma), and two patients succumbed from unrelated medical causes (both
had metastatic cutaneous tumours). The mean follow-up forthose alive is 65.9 months and mean
follow-up for those deceased is 15.3 months.
Conclusions: In the absence of systemic spread, parotid metastases from primary cutaneous
squamous cell carcinoma should be treated aggressively, while metastases from non-cutaneous
primary tumours should be approached with caution.
INTRODUCTION
Primary benign tumours form the majority of
lesions seen commonly in the parotid gland.
Metastatic lesions are rare and often associated
with cutaneousprimarymalignancies inthehead
and neck, although adenocarcinoma and rare
metastatic lesions have been reported. As part of
a combined oncology team, the head and neck
surgeonwillbefacedwiththedilemmaofmaking
a decision on the optimum management ofthese
cases.
MATERIALS AND METHODS
A retrospective review of 13 patients with
metastaticlesionsintheparotidtreatedunderone
surgeon in the Department of Otolaryngology -
Head and Neck Surgery at the Royal Victoria
Hospital, Belfast, United Kingdom was
undertaken (Table). Variables documented
included age and sex of patients, histology of
tumours, primary site of tumours, clinical
presentation, latent period to secondary tumour,
preoperative facial nerve function, treatment
instituted, postoperative facial nerve function,
follow-up and survival.
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TABLE
Diagnoses and outcomes ofpatients withparotid metastases
Case Age, year Sex Histology Latent Treatment Postoperative Follow-up Survival Survival
period to FacialNerve to date, to death,
secondary Function month month
tumour,
month
1-8 mean 65.4 7 M: 1 F SCC mean 28.4 6 x Total 5 Normal 4 Alive: mean 62.8 mean 16.3
Parotidectomy +
range (59-76) range (13-62) Post-op XRT: 3 Compromised 4 Dead* range (40-86) range(13-22)
2 x Total
Parotidectomy + VII
sacrifice + MRND +
Latissimus Dorsi flap
+ Post-op
XRT
9-11 mean 54.3 1 M: 2F Adeno Ca mean 29.7 3 x Total 2Normal: 1 Alive: 73 mean 13.5
Parotidectomy +
range (52-58) range (13-61) Post-ophormonal 1 Compromised 2 Dead range(l3-14)
manipulation
12 59 M Basisquamous 63 Superficial Normal Alive 74
Carcinoma Parotidectomy
13 63 F melanoma 8 Induction Normal Alive 63
Chemotherapy +
XRT + Total
Parotidectomy +
MRND + Latissimus
Dorsi flap
+ Post-op Alpha-
Interferon
M Male
F Female
SCC Squamous cell carcinoma
AdenoCa
XRT
MRND
Adenocarcinoma
Radiotherapy
Modified radical neck dissection
* 2 of 4 patients with squamous cell carcinoma died from non-tumour related pulmonary and cardiac causes
RESULTS
As shown intheTable, there wereninemales and
four females with an age range of 52-76 years
(mean 62.2 years). Histologically, there was a
predominance ofsquamous cell carcinoma, with
adenocarcinomaformingthesecondlargestgroup
and the remaining, being isolated, unusual
metastatic lesions. Ten of the 13 cases had a
cutaneousprimarytumouroriginatinginthehead
and neck region with the most favoured sites
being the scalp and the pinna (Figure). The
majority of these cases from cutaneous primary
tumours were squamous cell carcinoma in type.
There were three patients with metastatic
adenocarcinoma; two from breast primary
tumours, andonefromaprostaticprimarytumour.
A mass in the parotid was the sole feature in all
cases. All patients, at presentation, had an intact
functioning facial nerve on the side ofthe lesion.
All patients underwent a thorough ENT and
general examination, fine needle aspiration
cytology of the parotid and Computed
Tomography (CT) scans ofthe parotid, neck and
chest. Those with cutaneous metastatic lesions
were patients who had undergone treatment for
their scalp, pinna and neck lesions previously
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Fig. Sites of the primary tumours of skin which have
metastasized to the parotid gland.
under our care. The breast carcinoma patients
hadbeenthoroughlyevaluatedbythebreastteam
toruleoutothersystemic metastases withCTand
radioisotope bone scans, while the prostatic
carcinoma patient had a thorough genitourinary
work-upbeforebeingreferredtoourdepartment.
The latent period following the primary
malignancy was variable, ranging from 8 months
to63 months (mean29.8 months). Themalignant
melanomawas extremely aggressive andwas the
only metastatic lesion in our series that appeared
within a year oftreatment ofthe primary lesion.
Thetreatmentoptionsemployedvarieddepending
on the extent ofthe lesion as seen on the CT scan
and the histology of the primary lesion. Cases
with squamous cell carcinoma underwent either
total parotidectomy with post-operative
radiotherapy, or total parotidectomy with facial
nervesacrifice, amodifiedradicalneckdissection
andlatissimus dorsiflap forskin cover, followed
by post-operative radiotherapy. The three cases
of metastatic adenocarcinoma underwent total
parotidectomy with preservation of the facial
nerve followed by post-operative hormonal
therapy;tamoxifenforthebreastcarcinomacases,
and goserelin for the single prostatic carcinoma
case. The basisquamous carcinoma presented as
a 1cmdiametersinglemetastasisinthesuperficial
lobe, andwascompletelyexcisedby asuperficial
parotidectomy. The malignant melanoma
presented as a very large metastatic lesion
involving the parotid and the neck. This was
considered unsuitable for primary surgery and
the patient underwent induction chemotherapy
with cisplatin and 5-fluorouracil followed by
radiotherapy to initially shrink the mass, then
followed by a total parotidectomy with facial
nerve preservation, modified radical neck
dissection and latissimus dorsi flap. Post-
operatively, the patient was treated with alfa-
interferon for a period of 18 months.
At their last follow-up, four of the 13 (30.8%)
patients suffered from facial nerve function
compromise; in two of these cases the facial
nerve hadbeen intentionally sacrificed. Seven of
the 13 patients (53.8%) are alive without any
evidence of recurrence, and a mean survival to
dateof65.9 months (range40- 86months). Sixof
the 13 patients (46.2%) have died with a mean
survival to death of 15.3 months (range 13-22
months), although two of them died from non-
tumour related causes.
DISCUSSION
Metastatic disease accounts for approximately 9
to 14% of all parotid tumours.' Cutaneous
malignant melanoma and squamous cell
carcinoma of the head and neck region account
for approximately 80% of these metastases.2
Seven of our 13 patients (53.8%) are alive and
well, with six ofthese seven having had primary
cutaneous tumours. Three of our patients (two
with squamous cell carcinomas and one with
basisquamous carcinoma) are now considered
cured, having survived at least, five years since
treatment oftheirparotid secondary tumour. In a
123-patientstudyofpatientstreatedaggressively
for metastatic parotid disease from cutaneous
primary tumours, O'Brien et al 3 have reported
cumulative disease-specific five-year survival
rates of 58% in those with metastatic cutaneous
squamous cell carcinoma, and 40% in metastatic
malignant melanoma. In our series, 60% (6/10)
of our patients with metastases secondary to
cutaneous primary tumours have no evidence of
recurrence at their last review, and 20% (2/10)
succumbed to causes unrelated to the original
malignancy (cardiac and pulmonary).
In a review of 866 reported cases of parotid
metastases, Pisani et al 4 found that 92 cases
( 1%)originatedfromaninfraclavicularprimary
tumour, indicating that a metastatic lesion in the
parotid needs to be assessed and investigated
quite differently from a lateral neck mass.
Infraclavicularprimarytumourstendtooriginate
in the lung, kidney, breast and gastrointestinal
tract, although unusual sites such as
adenocarcinoma of the urachus have been
reported.5-7 Cases with infraclavicular primary
tumours generally have a poorer prognosis,
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although therehavebeenoccasional documented
cases with a good outcome.5'7 Cases with parotid
metastases from non-cutaneous head and neck
primary tumours also have a poorer prognosis,
with a reported five-year survival rate of only
10%. In our series, two out of the three patients
with parotid metastases from non-cutaneous
infraclavicularprimarytumourshavesuccumbed
to their disease.
O'Brien et al I quoted a 26% incidence of
clinicallyinvolvednodesincaseswithmetastatic
squamous cell carcinoma to the parotid, and a
further 35% of those having elective neck
dissections had positive histology in the neck.
These results are indicative of the likelihood of
dissemination ofmetastatic cutaneous squamous
cell carcinoma to the parotid, and indicate that
treatmentoftheneckshouldbeanintegralpartof
the overall therapeutic plan, either in the form of
an elective neck dissection or post-operative
radiotherapy to the neck. Total parotidectomy
with preservation ofthe facial nerve followed by
post-operative radiotherapy to the parotid and
neck would be the protocol we suggest for most
tumours restrictedtotheparotid, withoutclinical
involvement ofnecknodes. The facial nerve was
preserved attimeofsurgery in 11 ofour 13 cases,
with nine of these 1 1 cases now having normal
post-operative facial nerve function. The facial
nerve may, however, need to be sacrificed for
larger parotid tumours involving the overlying
skin, whereby preservation ofthe nerve (whether
involved or not by tumour) may compromise
surgical margins. These cases may also warrant
an additional modified radical neck dissection
and latissimus dorsi flap for skin cover, followed
by postoperative radiotherapy.
Imagingisimportantifametastaticparotidtumour
is suspected, either for diagnosis or to delineate
its size and invasive nature. The majority of
tumours appear as low signal on magnetic
resonance imaging (MRI) Ti weighting and as
high signal on MRI T2 weighting. However, the
paramagnetic effectofmelanin causes melanotic
deposits to appear instead as high signal on MRI
TI weightingandlowsignalonMRIT2weighting,
thus aiding in the diagnosis of malignant
melanoma.8 In a study of 54 patients with
aggressivenon-melanomaskincancerofthehead
and neck, 23 were foundto have metastasis to the
parotid or direct invasion of the gland, requiring
parotidectomy for locoregional control of their
disease.9However, parotidinvolvementwas only
diagnosed clinically in six of these 23 patients,
with the remaining 17 cases identified by CT
scanning and MRI studies. Younger patients (51
vs75 years)weremorelikelytohavelesionswith
perineural invasion (P = 0.006), suggested by
facial nerve enhancement or thickening, on
scanning. Despite parotidectomy, these 23
patients had more disease recurrence compared
to the rest of the cohort without parotid
involvement (P=0.0002). Identification ofthese
high-risk lesions at initial presentation, and
aggressive treatment with surgery followed by
post-operative radiotherapy still offers the best
chance of cure for these patients.
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